A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations

Clinical trial NCT00148512 · COMPLETED

Trial details

NCT number: NCT00148512
Sponsor: Boehringer Ingelheim
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Parkinson Disease

Start date: 2003-03-01
Primary completion: 2005-02-01
Enrollment: 254

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.